<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               4	CONTRAINDICATIONS<BR>               <BR>                  Contraindications to peginterferon alfa and ribavirin also apply to INCIVEK combination treatment.<BR>                  INCIVEK combination treatment is contraindicated in:<BR>                  <BR>                      women who are or may become pregnant. Ribavirin may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug treatment, the patient should be apprised of the potential hazard to a fetus [see<BR>                            Warnings and Precautions (5.3), Use in Specific Populations (8.1), and<BR>                            Patient Counseling Information (17.2)<BR>                        ].<BR>                      men whose female partners are pregnant.<BR>                  <BR>                  <BR>                     INCIVEK is a strong inhibitor of CYP3A. INCIVEK is contraindicated when combined with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). INCIVEK is contraindicated when combined with drugs that strongly induce CYP3A and thus may lead to lower exposure and loss of efficacy of INCIVEK. Contraindicated drugs are listed below in Table 3 [also see<BR>                            Drug Interactions (7), <BR>                        Table 5 and <BR>                           Clinical Pharmacology (12.3),<BR>                         Tables 6 and 7].<BR>                  <BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="75%" ID="table3"><BR>                     <caption>Table 3: Drugs that are Contraindicated with INCIVEK</caption><BR>                     <col width="33%" align="left" valign="middle"/><BR>                     <col width="34%" align="left" valign="middle"/><BR>                     <col width="33%" align="left" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule Rrule">Drug Class</th><BR>                           <th styleCode="Rrule">Drugs within Class that are Contraindicated with INCIVEK</th><BR>                           <th styleCode="Rrule">Clinical Comments</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Alpha 1-adrenoreceptor antagonist</td><BR>                           <td styleCode="Rrule">Alfuzosin</td><BR>                           <td styleCode="Rrule">Potential for hypotension or cardiac arrhythmia</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Antimycobacterials</td><BR>                           <td styleCode="Rrule">Rifampin</td><BR>                           <td styleCode="Rrule">Rifampin significantly reduces telaprevir plasma concentrations.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Ergot derivatives</td><BR>                           <td styleCode="Rrule">Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td><BR>                           <td styleCode="Rrule">Potential for acute ergot toxicity characterized by peripheral vasospasm or ischemia</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">GI motility agent</td><BR>                           <td styleCode="Rrule">Cisapride</td><BR>                           <td styleCode="Rrule">Potential for cardiac arrhythmias</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Herbal products</td><BR>                           <td styleCode="Rrule">St. John's wort (<content styleCode="italics">Hypericum perforatum</content>)</td><BR>                           <td styleCode="Rrule">Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St. John's wort.</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">HMG-CoA reductase inhibitors</td><BR>                           <td styleCode="Rrule">Lovastatin, simvastatin </td><BR>                           <td styleCode="Rrule">Potential for myopathy including rhabdomyolysis</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Neuroleptic</td><BR>                           <td styleCode="Rrule">Pimozide</td><BR>                           <td styleCode="Rrule">Potential for serious and/or life-threatening adverse reactions such as cardiac arrhythmias</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">PDE5 inhibitor</td><BR>                           <td styleCode="Rrule">Sildenafil (Revatio<sup>&#174;</sup>) or tadalafil (Adcirca<sup>&#174;</sup>) [for treatment of pulmonary arterial hypertension]<footnote ID="table3a">See <content styleCode="italics"><BR>                                    <linkHtml href="#table5">Drug Interactions, Table 5</linkHtml><BR>                                 </content> for co-administration of sildenafil and tadalafil when dosed for erectile dysfunction.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">Potential for PDE5 inhibitor-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Sedatives/hypnotics</td><BR>                           <td styleCode="Rrule">Orally administered midazolam<footnote ID="table3b">See <content styleCode="italics"><BR>                                    <linkHtml href="#table5">Drug Interactions, Table 5 </linkHtml><BR>                                 </content>for parenterally administered midazolam.</footnote>, triazolam</td><BR>                           <td styleCode="Rrule">Prolonged or increased sedation or respiratory depression</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>               <BR><BR><BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                            All contraindications to peginterferon alfa and ribavirin also apply since INCIVEK must be administered with peginterferon alfa and ribavirin. (4)<BR>                            Pregnant women and men whose female partners are pregnant: Because ribavirin may cause birth defects and fetal death, telaprevir in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant. (4, 5.3, 8.1, 17.2)<BR>                            Co-administration with drugs that:<BR>                                 are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. (4)<BR>                                 strongly induce CYP3A which may lead to lower exposure and loss of efficacy of INCIVEK. (4)<BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>